Home › Sistema ng Imunidad at mga Karamdaman › Virginia
Pag-aaral pangklinika para sa Sistema ng Imunidad at mga Karamdaman sa Virginia
7 pag-aaral para sa Sistema ng Imunidad at mga Karamdaman ang naghahanap ng mga kalahok sa mga site sa Virginia.
Mga Lungsod sa Virginia
Opisyal na teksto ng pag-aaral (English)
A Study to Learn About the Study Medicine Called Tilrekimig in People With Moderate-to Severe Eczema
- Alexandria Associates in Dermatology, Arlington
Nagre-recruitPhase 3
Edad 12 pataas · Lahat ng kasarian · Na-update Nob 6, 2026 · NCT07783425Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- VCU Massey Comprehensive Cancer Center, Richmond
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT04242095A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Virginia Oncology Associates, Norfolk
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2026 · NCT06722235A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Virginia Oncology Associates, Norfolk
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 30, 2026 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Virginia Oncology Associates, Norfolk
- Virginia Commonwealth University-Massey Cancer Center, Richmond
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- University of Virginia Health System, Charlottesville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT04104776A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Virginia Commonwealth University, Richmond
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 15, 2025 · NCT06619561Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.